ProShares UltraShort NASDAQ Biotechnology
15 hedge funds and large institutions have $17M invested in ProShares UltraShort NASDAQ Biotechnology in 2015 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 6 closing their positions.
92% more call options, than puts
Call options by funds: $8.94M | Put options by funds: $4.65M
21% less funds holding
Funds holding: 19 → 15 (-4)
64% less capital invested
Capital invested by funds: $46.6M → $17M (-$29.6M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EM
Emancipation Management
New York
|
+$675K |
| 2 |
MC
Moors & Cabot
Boston,
Massachusetts
|
+$238K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$62K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$7.98M |
| 2 |
VF
Virtu Financial
New York
|
-$5.61M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$2.89M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.99M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.7M |
BIS Hedge Fund Activity: Q4 2015 in Review
15 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2015, worth a combined $17M — down 64% from $46.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BIS and 2 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was Emancipation Management, opening a new position worth an estimated $675K. The largest seller was Ardsley Advisory Partners, cutting an estimated $7.98M.
- 15 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2015, down from 19 in Q3 2015.
- Funds reported $17M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2015, down 64% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2015 and 6 closed out, a net change of -4 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2015 was Emancipation Management, an estimated $675K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2015 was Ardsley Advisory Partners, an estimated $7.98M sold.
Based on aggregated 13F filings for Q4 2015.